New agent improves kidney transplant survival in mice, likely to speed replacement of other organs

New research published online in the FASEB Journal details a new antibody, called "OPN-305" that may significantly improve survival outcomes for those receiving donated kidneys and other organs. OPN-305 works by preventing inflammation triggered by oxygen deprivation in the donated organ, allowing for better recovery after transplantation. Specifically, it binds to sensors on transplant tissue, called "toll-like receptors" or "TLR-2," in the circulating blood and turns off signals that provoke inflammation. In addition, the compound is likely to extend the life of a donated organ after it has been transplanted.

"Although the work was carried out with kidney transplants, it is likely that other types of transplants could benefit. Other common types of , needed for liver or heart or lung disease, are also vulnerable to damage induced by the transplant procedure, especially where there has been a long period of cold storage without a normal blood supply," said Steven H. Sacks, study author from the MRC Centre for Transplantation at King's College School of Medicine in London. "For other medical conditions such as stroke and heart attack, where the blood flow to vital organs is blocked, it is highly possible that this new treatment may also make recovery more complete."

Sacks and colleagues made this discovery using two groups of mice receiving kidney transplants. The first was treated with OPN-305 and the second was given an irrelevant agent. The group treated with the OPN-305 showed good recovery of function in the transplanted organ, whereas the control treatment had no effect and the animals developed severe organ damage. Researchers say a clinical trial design using a similar antibody for use in human patients is underway.

"This new antibody is exciting because it basically increases the 'shelf life' of organs that are critically needed for transplantation," said Gerald Weissmann, M.D., Editor-in-Chief of the . "Since it is directed against molecules that regulate inflammation, OPN-305 is likely to extend the lifespan of any other transplanted organs. Although human trials have not yet begun, this work identifies TLR's as targets for drugs to reduce inflammation and organ rejection."

add to favorites email to friend print save as pdf

Related Stories

Kidney transplants: Expanding the pool of available organs

May 20, 2010

In the United States over 80,000 people are on the kidney transplant waiting list, and thousands die each year waiting for transplants. For most dialysis patients, kidney transplantation increases their chances of survival.

Recommended for you

Cold cash just keeps washing in from ALS challenge

Aug 28, 2014

In the couple of hours it took an official from the ALS Association to return a reporter's call for comment, the group's ubiquitous "ice bucket challenge" had brought in a few million more dollars.

Medtronic spends $350M on another European deal

Aug 27, 2014

U.S. medical device maker Medtronic is building stronger ties to Europe, a couple months after announcing a $42.9 billion acquisition that involves moving its main executive offices across the Atlantic, where it can get a ...

Mind over matter for people with disabilities

Aug 26, 2014

People with serious physical disabilities are unable to do the everyday things that most of us take for granted despite having the will – and the brainpower – to do so. This is changing thanks to European ...

User comments